Igenomix is a medical testing laboratory specializing in reproductive genetic services. Together with clinics and fertility specialists worldwide, we investigate human reproduction to change the lives of those who are trying to conceive. In 2021, Vitrolife acquired Igenomix, founded in 2011. Together we create Vitrolife Group, a global leader in reproductive health.
By combining Igenomix’s portfolio of reproductive genetic testing services with Vitrolife’s best-in-class IVF device portfolio, we support clinics and patients across the fertility journey. Currently, Vitrolife Group are approximately 1,100 people worldwide headquartered in Gothenburg, Sweden. Our vision is to enable people to fulfill the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. Together we create excellence in reproductive health. The Vitrolife AB (publ) share is listed on Nasdaq Stockholm.